Samuel Kintz is CEO & President at Enliven Therapeutics, Inc. (ELVN). They have made 1 open-market trade across 1 company since 2023, most recently 2025-11-17.
CIK 0001967168
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ELVN | 890,392 | $33.3M |
Shares reported on the most recent Form 4, priced at the 2025-11-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ELVN | SELL · 10b5-1 | 2025-11-17 | 2025-11-19 | $21.82 | $273K | -8.5% | -24.9% | +16.3% |
| ELVN | SELL · 10b5-1 | 2025-10-17 | 2025-10-21 | $21.33 | $267K | +10.5% | +0.4% | +27.7% |
| ELVN | SELL · 10b5-1 | 2025-09-26 | 2025-09-30 | $20.06 | $74K | +2.2% | +17.7% | -21.7% |
| ELVN | SELL · 10b5-1 | 2025-09-23 | 2025-09-25 | $20.03 | $56K | +8.3% | +15.2% | -9.9% |
| ELVN | SELL · 10b5-1 | 2025-09-17 | 2025-09-19 | $19.28 | $116K | +5.3% | +17.5% | -11.4% |
| ELVN | SELL · 10b5-1 | 2025-08-20 | 2025-08-21 | $20.00 | $30K | +4.8% | -0.4% | +10.6% |
| ELVN | SELL · 10b5-1 | 2025-08-18 | 2025-08-20 | $20.02 | $428K | +6.3% | -3.6% | +14.9% |
| ELVN | SELL · 10b5-1 | 2025-07-17 | 2025-07-21 | $22.71 | $473K | -13.0% | -9.0% | +2.4% |
| ELVN | SELL · 10b5-1 | 2025-06-17 | 2025-06-18 | $22.14 | $509K | -9.7% | +4.1% | -15.3% |
| ELVN | SELL · 10b5-1 | 2025-06-03 | 2025-06-05 | $20.05 | $150K | +0.1% | -10.1% | -3.8% |
| ELVN | SELL · 10b5-1 | 2025-05-19 | 2025-05-21 | $16.49 | $165K | +30.1% | +26.8% | +17.6% |
| ELVN | SELL · 10b5-1 | 2025-05-01 | 2025-05-05 | $20.07 | $257K | -11.7% | +10.4% | -7.2% |
| ELVN | SELL · 10b5-1 | 2025-04-17 | 2025-04-21 | $16.42 | $164K | +20.7% | +2.9% | +32.9% |
| ELVN | SELL · 10b5-1 | 2025-03-17 | 2025-03-19 | $20.83 | $521K | -3.9% | -20.8% | +6.4% |
| ELVN | SELL · 10b5-1 | 2024-10-18 | 2024-10-22 | $30.00 | $28K | -3.8% | -11.6% | -23.4% |
| ELVN | SELL · 10b5-1 | 2024-10-08 | 2024-10-10 | $28.06 | $1.7M | +8.3% | +3.3% | -9.8% |
| ELVN | SELL · 10b5-1 | 2024-10-04 | 2024-10-08 | $27.51 | $747K | +4.1% | +4.1% | -13.6% |
| ELVN | SELL · 10b5-1 | 2024-10-01 | 2024-10-03 | $27.54 | $14K | +6.5% | +5.9% | -8.5% |
| ELVN | SELL · 10b5-1 | 2024-08-26 | 2024-08-28 | $22.89 | $275K | +2.8% | +6.6% | +7.6% |
| ELVN | SELL · 10b5-1 | 2024-07-31 | 2024-08-02 | $27.56 | $125K | +3.6% | +5.5% | +32.3% |
| ELVN | SELL · 10b5-1 | 2024-07-25 | 2024-07-29 | $24.92 | $597K | -18.8% | -16.3% | +7.1% |
| ELVN | SELL · 10b5-1 | 2024-06-25 | 2024-06-27 | $21.65 | $507K | -1.9% | +13.0% | +3.1% |
| ELVN | SELL · 10b5-1 | 2024-05-28 | 2024-05-30 | $23.18 | $554K | -1.7% | +1.4% | +0.1% |
| ELVN | SELL · 10b5-1 | 2024-04-25 | 2024-04-29 | $16.89 | $203K | +33.3% | +19.0% | +48.1% |
| ELVN | SELL · 10b5-1 | 2024-04-11 | 2024-04-15 | $25.04 | $2.4M | -14.3% | +22.6% | +28.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.